...
search icon
alny-img

Alnylam Pharmaceuticals Inc, Common Stock

ALNY

NSQ

$234.56

+$4.06

(1.76%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$31.06B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
601.35K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$141.98 L
$304.39 H
$234.56

About Alnylam Pharmaceuticals Inc, Common Stock

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALNYSectorS&P500
1-Week Return3.66%1.04%0.24%
1-Month Return-7.33%-7.14%-7.32%
3-Month Return-4.75%-2.78%-12.05%
6-Month Return-20.96%-10.56%-9.73%
1-Year Return61.41%-1.55%5.05%
3-Year Return49.71%-0.6%20.03%
5-Year Return69.38%35.24%83.31%
10-Year Return100.51%85.96%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue492.85M844.29M1.04B1.83B2.25B[{"date":"2020-12-31","value":21.92,"profit":true},{"date":"2021-12-31","value":37.55,"profit":true},{"date":"2022-12-31","value":46.14,"profit":true},{"date":"2023-12-31","value":81.32,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue78.05M140.14M168.82M310.41M323.37M[{"date":"2020-12-31","value":24.14,"profit":true},{"date":"2021-12-31","value":43.34,"profit":true},{"date":"2022-12-31","value":52.21,"profit":true},{"date":"2023-12-31","value":95.99,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit414.80M704.14M868.60M1.52B1.92B[{"date":"2020-12-31","value":21.55,"profit":true},{"date":"2021-12-31","value":36.58,"profit":true},{"date":"2022-12-31","value":45.13,"profit":true},{"date":"2023-12-31","value":78.86,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin84.16%83.40%83.73%83.02%85.62%[{"date":"2020-12-31","value":98.3,"profit":true},{"date":"2021-12-31","value":97.41,"profit":true},{"date":"2022-12-31","value":97.79,"profit":true},{"date":"2023-12-31","value":96.97,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses1.24B1.41B1.65B1.80B2.10B[{"date":"2020-12-31","value":59.15,"profit":true},{"date":"2021-12-31","value":67.22,"profit":true},{"date":"2022-12-31","value":78.68,"profit":true},{"date":"2023-12-31","value":85.65,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(828.44M)(708.65M)(785.07M)(282.18M)(176.88M)[{"date":"2020-12-31","value":-82843800000,"profit":false},{"date":"2021-12-31","value":-70865200000,"profit":false},{"date":"2022-12-31","value":-78507200000,"profit":false},{"date":"2023-12-31","value":-28217500000,"profit":false},{"date":"2024-12-31","value":-17688500000,"profit":false}]
Total Non-Operating Income/Expense(99.85M)(284.93M)(473.08M)(177.00M)(21.92M)[{"date":"2020-12-31","value":-9984900000,"profit":false},{"date":"2021-12-31","value":-28493400000,"profit":false},{"date":"2022-12-31","value":-47308100000,"profit":false},{"date":"2023-12-31","value":-17700200000,"profit":false},{"date":"2024-12-31","value":-2192000000,"profit":false}]
Pre-Tax Income(855.60M)(852.14M)(1.13B)(433.52M)(178.94M)[{"date":"2020-12-31","value":-85560000000,"profit":false},{"date":"2021-12-31","value":-85214400000,"profit":false},{"date":"2022-12-31","value":-112699300000,"profit":false},{"date":"2023-12-31","value":-43351700000,"profit":false},{"date":"2024-12-31","value":-17893900000,"profit":false}]
Income Taxes2.68M680.00K4.16M6.72M99.22M[{"date":"2020-12-31","value":2.7,"profit":true},{"date":"2021-12-31","value":0.69,"profit":true},{"date":"2022-12-31","value":4.2,"profit":true},{"date":"2023-12-31","value":6.78,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(858.28M)(852.82M)(1.13B)(440.24M)(278.16M)[{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false},{"date":"2024-12-31","value":-27815700000,"profit":false}]
Income From Continuous Operations(858.28M)(852.82M)(1.13B)(440.24M)(278.16M)[{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false},{"date":"2024-12-31","value":-27815700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(858.28M)(852.82M)(1.13B)(440.24M)(278.16M)[{"date":"2020-12-31","value":-85828100000,"profit":false},{"date":"2021-12-31","value":-85282400000,"profit":false},{"date":"2022-12-31","value":-113115600000,"profit":false},{"date":"2023-12-31","value":-44024200000,"profit":false},{"date":"2024-12-31","value":-27815700000,"profit":false}]
EPS (Diluted)(7.66)(7.12)(8.66)(3.56)(1.46)[{"date":"2020-12-31","value":-766,"profit":false},{"date":"2021-12-31","value":-712,"profit":false},{"date":"2022-12-31","value":-866,"profit":false},{"date":"2023-12-31","value":-356,"profit":false},{"date":"2024-12-31","value":-146,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALNY
Cash Ratio 2.27
Current Ratio 2.78
Quick Ratio 2.71

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALNY
ROA (LTM) -2.74%
ROE (LTM) -1500.66%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALNY
Debt Ratio Lower is generally better. Negative is bad. 0.98
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.02

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALNY
Trailing PE NM
Forward PE 833.33
P/S (TTM) 13.50
P/B 452.51
Price/FCF NM
EV/R 12.88
EV/Ebitda 204.85
PEG NM

FAQs

What is Alnylam Pharmaceuticals Inc share price today?

Alnylam Pharmaceuticals Inc (ALNY) share price today is $234.56

Can Indians buy Alnylam Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Alnylam Pharmaceuticals Inc (ALNY) on Vested. To buy Alnylam Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALNY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Alnylam Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Alnylam Pharmaceuticals Inc (ALNY) via the Vested app. You can start investing in Alnylam Pharmaceuticals Inc (ALNY) with a minimum investment of $1.

How to invest in Alnylam Pharmaceuticals Inc shares from India?

You can invest in shares of Alnylam Pharmaceuticals Inc (ALNY) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALNY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Alnylam Pharmaceuticals Inc shares
What is Alnylam Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Alnylam Pharmaceuticals Inc (ALNY) is $304.39. The 52-week low price of Alnylam Pharmaceuticals Inc (ALNY) is $141.98.

What is Alnylam Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Alnylam Pharmaceuticals Inc (ALNY) is 452.51

What is the Market Cap of Alnylam Pharmaceuticals Inc?

The market capitalization of Alnylam Pharmaceuticals Inc (ALNY) is $31.06B

What is Alnylam Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Alnylam Pharmaceuticals Inc is ALNY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top